Oragenics Inc (OGEN)

$0.60 +0.01 (1.95%)
Market Cap 2.66M
Revenue (ttm) 0.00
Net Income (ttm) -9.84M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 24,755
Avg Vol 148,548
Day's Range N/A - N/A
Shares Out 4.51M
Stochastic %K 36%
Beta 1.26
Analysts Strong Buy
Price Target $2.00

Company Profile

Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification for the treatment of mild traumatic brain...

Industry: Biotechnology
Sector: Healthcare
Phone: 813 286 7900
Address:
9015 Town Center Parkway, Suite 143, Lakewood Ranch, United States
NMax
NMax May. 18 at 4:26 PM
$OGEN Racketqueen spent his whole weekend crying about a stock he claims to have sold in march of 2025. Correction... Racketqueen spent his weekend crying about a stock he shorted and criminally manipulated, because noone will sell and help that idiot cover. 😁 Continuing to accumulate!! 🤑🤑🤑
0 · Reply
RocketQueen
RocketQueen May. 18 at 3:35 PM
$OGEN one massive risk here is they won't be able to proceed with any US regulatory applications with potential failure in the Australia data readouts. The only catalysts that might bring in a few cents in the full enrollment before they do the readouts. My suggestion is to sell your entire position into full enrollment status.
0 · Reply
RocketQueen
RocketQueen May. 18 at 3:30 PM
$OGEN news out, and this only goes up one cent. lol Looks like investors have given up on this scam.
0 · Reply
focafoca99
focafoca99 May. 18 at 1:59 PM
$OGEN initiates its Australian Phase IIa trial rollout with sites activated and first patient dosed, and signs an LOI for a CNS medical https://www.rapidticker.com/news/ogen-oragenics-provides-investor-update-010fae
0 · Reply
NMax
NMax May. 18 at 1:31 PM
$OGEN Delighted to continue accumulating here!! 🤑🤑🤑
0 · Reply
RocketQueen
RocketQueen May. 17 at 11:49 PM
$OGEN all you can eat dilution and reverse splits.....
0 · Reply
RocketQueen
RocketQueen May. 16 at 3:27 PM
$OGEN never-ending biotech PONZI scam with constant dilution, reverse splits, and pivots to new (blood laundering) garbage can ideas to stay afloat.
0 · Reply
RocketQueen
RocketQueen May. 15 at 10:09 PM
$OGEN dilution, reverse split or possibly chapter 11 around the corner.
0 · Reply
NMax
NMax May. 15 at 5:58 PM
$OGEN I'm actually doing the most accumulating I've ever done here. And I fully expect to continue increasing the rate of accumulation. Happy to be here. My average is loving it! 🤑🤑🤑
0 · Reply
RocketQueen
RocketQueen May. 15 at 4:38 PM
$OGEN scam and fraud company. Nobody in their right mind is accumulating shares. Dilution, failed trials, another R/S , trash can pivot and possibly chapter 11 around the corner. The board should be in jail .
0 · Reply
Latest News on OGEN
ORAGENICS PROVIDES INVESTOR UPDATE

May 18, 2026, 8:30 AM EDT - 4 hours ago

ORAGENICS PROVIDES INVESTOR UPDATE

Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation

May 7, 2026, 8:30 AM EDT - 11 days ago

Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation

Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury.

May 5, 2026, 8:30 AM EDT - 13 days ago

Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury.

Oragenics announces 8 drug doses administered in Phase IIa trial of ONP-002

2026-04-20T14:01:13.000Z - 4 weeks ago

Oragenics announces 8 drug doses administered in Phase IIa trial of ONP-002

Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury

Apr 13, 2026, 8:30 AM EDT - 5 weeks ago

Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury

Oragenics receives audit opinion with going concern explanation

2026-03-25T22:35:16.000Z - 7 weeks ago

Oragenics receives audit opinion with going concern explanation

Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation

Mar 25, 2026, 6:30 PM EDT - 7 weeks ago

Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation

Oragenics files annual report on Form 10-K

2026-03-17T12:49:42.000Z - 2 months ago

Oragenics files annual report on Form 10-K

Oragenics initiates Phase IIa clinical trial site activation

2026-03-12T12:48:45.000Z - 2 months ago

Oragenics initiates Phase IIa clinical trial site activation

ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION

Mar 12, 2026, 8:30 AM EDT - 2 months ago

ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION

Oragenics explores potential acquisition of additional assets in CNS space

2026-03-11T12:45:33.000Z - 2 months ago

Oragenics explores potential acquisition of additional assets in CNS space

ORAGENICS EXPLORES EXPANSION OF CNS PLATFORM PURSUING ACQUISTION OF ASSETS IN BRAIN HEALTH, RECOVERY, AND NEUROPROTECTION

Mar 11, 2026, 8:30 AM EDT - 2 months ago

ORAGENICS EXPLORES EXPANSION OF CNS PLATFORM PURSUING ACQUISTION OF ASSETS IN BRAIN HEALTH, RECOVERY, AND NEUROPROTECTION

Oragenics receives HREC approval for Phase IIa trial of ONP-002 in Australia

2026-03-10T12:42:00.000Z - 2 months ago

Oragenics receives HREC approval for Phase IIa trial of ONP-002 in Australia

Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia

Mar 10, 2026, 8:30 AM EDT - 2 months ago

Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia

Oragenics previews targeted milestones for 2026

2026-02-09T13:46:12.000Z - 3 months ago

Oragenics previews targeted milestones for 2026

Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury Therapy

Feb 9, 2026, 8:30 AM EST - 3 months ago

Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury Therapy

Oragenics partners with Duck Flats Pharma to support FDA IND trial design

2026-02-03T13:40:46.000Z - 3 months ago

Oragenics partners with Duck Flats Pharma to support FDA IND trial design

Oragenics Partners with DUCK FLATS Pharma to Support FDA IND Readiness and Clinical Trial Design for Concussion Program

Feb 3, 2026, 8:30 AM EST - 3 months ago

Oragenics Partners with DUCK FLATS Pharma to Support FDA IND Readiness and Clinical Trial Design for Concussion Program

Oragenics files $100M mixed securities shelf

2026-01-22T21:15:38.000Z - 4 months ago

Oragenics files $100M mixed securities shelf

Oragenics Q3 2025 Shareholder Update

Nov 12, 2025, 8:30 AM EST - 6 months ago

Oragenics Q3 2025 Shareholder Update

Oragenics regains compliance with NYSE

2025-10-21T12:15:12.000Z - 7 months ago

Oragenics regains compliance with NYSE

Oragenics Regains Full NYSE American Compliance, Company Resolves Stockholder Equity Deficiency

Oct 21, 2025, 8:00 AM EDT - 7 months ago

Oragenics Regains Full NYSE American Compliance, Company Resolves Stockholder Equity Deficiency

Oragenics, Receptor.AI partner to accelerate pipeline development

2025-10-07T13:20:29.000Z - 7 months ago

Oragenics, Receptor.AI partner to accelerate pipeline development

Oragenics Announces Strategic Partnership with Receptor.AI to Accelerate Pipeline Development

Oct 7, 2025, 8:30 AM EDT - 7 months ago

Oragenics Announces Strategic Partnership with Receptor.AI to Accelerate Pipeline Development

Oragenics reports Q2 EPS ($3.10) vs. ($15.27) last year.

2025-08-11T12:50:19.000Z - 10 months ago

Oragenics reports Q2 EPS ($3.10) vs. ($15.27) last year.

Oragenics Q2 2025 Shareholder Update

Aug 11, 2025, 8:45 AM EDT - 10 months ago

Oragenics Q2 2025 Shareholder Update

Oragenics selects South Star Research as its CRO for ONP-002 Phase IIa trial

2025-07-31T12:52:03.000Z - 10 months ago

Oragenics selects South Star Research as its CRO for ONP-002 Phase IIa trial

Oragenics announces manufacturing agreement with Sterling Pharma for ONP-002

2025-07-16T12:45:56.000Z - 10 months ago

Oragenics announces manufacturing agreement with Sterling Pharma for ONP-002

Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development

Jul 16, 2025, 8:39 AM EDT - 10 months ago

Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development

Oragenics Completes Approximately $16.5 Million Offering

Jul 2, 2025, 4:15 PM EDT - 11 months ago

Oragenics Completes Approximately $16.5 Million Offering

Why Is Oragenics Stock (OGEN) Down 55% Today?

2025-07-02T01:00:00.000Z - 11 months ago

Why Is Oragenics Stock (OGEN) Down 55% Today?

Oragenics trading resumes

2025-07-01T12:50:11.000Z - 11 months ago

Oragenics trading resumes

Oragenics prices 800,000 shares of Preferred Stock at $25.00 in public offering

2025-07-01T12:41:48.000Z - 11 months ago

Oragenics prices 800,000 shares of Preferred Stock at $25.00 in public offering

Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants

Jul 1, 2025, 8:31 AM EDT - 11 months ago

Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants

Oragenics trading halted, news pending

2025-07-01T12:05:53.000Z - 11 months ago

Oragenics trading halted, news pending

Oragenics trading resumes

2025-06-03T13:40:31.000Z - 1 year ago

Oragenics trading resumes

Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia

May 13, 2025, 8:30 AM EDT - 1 year ago

Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia

Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic Vision

May 12, 2025, 8:30 AM EDT - 1 year ago

Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic Vision

Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit

Apr 7, 2025, 4:30 PM EDT - 1 year ago

Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit

Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress

Mar 27, 2025, 8:30 AM EDT - 1 year ago

Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress

Oragenics, Inc. Announces Filing of 2024 Annual Report on Form 10-K

Mar 18, 2025, 5:33 PM EDT - 1 year ago

Oragenics, Inc. Announces Filing of 2024 Annual Report on Form 10-K

Oragenics, Inc. Submits Investigator's Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury (mTBI)

Mar 6, 2025, 9:30 AM EST - 1 year ago

Oragenics, Inc. Submits Investigator's Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury (mTBI)

Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Present at the Emergencies in Medicine Conference on Advancing Concussion Treatment

Feb 25, 2025, 8:30 AM EST - 1 year ago

Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Present at the Emergencies in Medicine Conference on Advancing Concussion Treatment

Oragenics, Inc. Announces Partnership with BRAINBox Solutions to Revolutionize Concussion Diagnosis and Treatment

Feb 11, 2025, 8:30 AM EST - 1 year ago

Oragenics, Inc. Announces Partnership with BRAINBox Solutions to Revolutionize Concussion Diagnosis and Treatment

Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Participate in the 12th Annual Brain Health Summit at the Leigh Steinberg Super Bowl Party 2025

Feb 5, 2025, 8:15 AM EST - 1 year ago

Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Participate in the 12th Annual Brain Health Summit at the Leigh Steinberg Super Bowl Party 2025

Oragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEO

Jan 21, 2025, 8:15 AM EST - 1 year ago

Oragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEO

Oragenics, Inc. Announces Conversion of Preferred Shares and Elimination of Liquidation Preference

Dec 16, 2024, 8:09 AM EST - 1 year ago

Oragenics, Inc. Announces Conversion of Preferred Shares and Elimination of Liquidation Preference

Oragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit

Oct 18, 2024, 8:30 AM EDT - 1 year ago

Oragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit

Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation

Oct 9, 2024, 7:30 AM EDT - 1 year ago

Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation

Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002

Oct 8, 2024, 8:45 AM EDT - 1 year ago

Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002

Oragenics, Inc. Announces Closing of Public Offering

Sep 5, 2024, 4:30 PM EDT - 1 year ago

Oragenics, Inc. Announces Closing of Public Offering

Oragenics, Inc. Announces Pricing of Public Offering

Sep 4, 2024, 8:36 AM EDT - 1 year ago

Oragenics, Inc. Announces Pricing of Public Offering

Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients

Aug 21, 2024, 8:45 AM EDT - 1 year ago

Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients

Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards

Aug 16, 2024, 4:30 PM EDT - 1 year ago

Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards

Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range

Aug 14, 2024, 8:30 AM EDT - 1 year ago

Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range

Oragenics, Inc. Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity Study

Aug 12, 2024, 8:30 AM EDT - 1 year ago

Oragenics, Inc. Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity Study

Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing

Aug 8, 2024, 8:45 AM EDT - 1 year ago

Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing

Oragenics Develops Automated Intranasal Device for Treating Concussed Patients

Jun 27, 2024, 8:30 AM EDT - 2 years ago

Oragenics Develops Automated Intranasal Device for Treating Concussed Patients

Oragenics, Inc. Announces Proposed Public Offering

Jun 24, 2024, 6:43 PM EDT - 2 years ago

Oragenics, Inc. Announces Proposed Public Offering

Oragenics Appoints William “Frank” Peacock MD as Chief Clinical Officer

May 22, 2024, 8:00 AM EDT - 2 years ago

Oragenics Appoints William “Frank” Peacock MD as Chief Clinical Officer

Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine

May 17, 2024, 8:00 AM EDT - 2 years ago

Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine

Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards

Apr 19, 2024, 5:50 PM EDT - 2 years ago

Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards

Oragenics, Inc. Files 10K and Provides Company Update

Apr 1, 2024, 9:05 AM EDT - 2 years ago

Oragenics, Inc. Files 10K and Provides Company Update

Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion

Mar 18, 2024, 7:00 AM EDT - 2 years ago

Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion

Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion

Mar 5, 2024, 7:45 AM EST - 2 years ago

Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion

Oragenics Announces Closing of Public Offering

Mar 1, 2024, 4:04 PM EST - 2 years ago

Oragenics Announces Closing of Public Offering

Oragenics Announces Pricing of Public Offering

Feb 27, 2024, 9:25 PM EST - 2 years ago

Oragenics Announces Pricing of Public Offering

Oragenics Announces Proposed Public Offering

Feb 27, 2024, 4:33 PM EST - 2 years ago

Oragenics Announces Proposed Public Offering

Oragenics, Inc. Announces Leadership Transition

Feb 12, 2024, 4:41 PM EST - 2 years ago

Oragenics, Inc. Announces Leadership Transition

NMax
NMax May. 18 at 4:26 PM
$OGEN Racketqueen spent his whole weekend crying about a stock he claims to have sold in march of 2025. Correction... Racketqueen spent his weekend crying about a stock he shorted and criminally manipulated, because noone will sell and help that idiot cover. 😁 Continuing to accumulate!! 🤑🤑🤑
0 · Reply
RocketQueen
RocketQueen May. 18 at 3:35 PM
$OGEN one massive risk here is they won't be able to proceed with any US regulatory applications with potential failure in the Australia data readouts. The only catalysts that might bring in a few cents in the full enrollment before they do the readouts. My suggestion is to sell your entire position into full enrollment status.
0 · Reply
RocketQueen
RocketQueen May. 18 at 3:30 PM
$OGEN news out, and this only goes up one cent. lol Looks like investors have given up on this scam.
0 · Reply
focafoca99
focafoca99 May. 18 at 1:59 PM
$OGEN initiates its Australian Phase IIa trial rollout with sites activated and first patient dosed, and signs an LOI for a CNS medical https://www.rapidticker.com/news/ogen-oragenics-provides-investor-update-010fae
0 · Reply
NMax
NMax May. 18 at 1:31 PM
$OGEN Delighted to continue accumulating here!! 🤑🤑🤑
0 · Reply
RocketQueen
RocketQueen May. 17 at 11:49 PM
$OGEN all you can eat dilution and reverse splits.....
0 · Reply
RocketQueen
RocketQueen May. 16 at 3:27 PM
$OGEN never-ending biotech PONZI scam with constant dilution, reverse splits, and pivots to new (blood laundering) garbage can ideas to stay afloat.
0 · Reply
RocketQueen
RocketQueen May. 15 at 10:09 PM
$OGEN dilution, reverse split or possibly chapter 11 around the corner.
0 · Reply
NMax
NMax May. 15 at 5:58 PM
$OGEN I'm actually doing the most accumulating I've ever done here. And I fully expect to continue increasing the rate of accumulation. Happy to be here. My average is loving it! 🤑🤑🤑
0 · Reply
RocketQueen
RocketQueen May. 15 at 4:38 PM
$OGEN scam and fraud company. Nobody in their right mind is accumulating shares. Dilution, failed trials, another R/S , trash can pivot and possibly chapter 11 around the corner. The board should be in jail .
0 · Reply
NMax
NMax May. 15 at 1:51 PM
$GME $CRSP $OGEN I see opportunity and I'm loving it!! Continuing to accumulate!! 🤑🤑🤑
0 · Reply
sincosine
sincosine May. 15 at 12:27 PM
$OGEN
0 · Reply
RocketQueen
RocketQueen May. 15 at 2:49 AM
$OGEN scam and fraud company. Upcoming dilution will sink retail investors and force another R/S. It might be best to sell and get out before you lose everything.
0 · Reply
Gev222
Gev222 May. 14 at 11:50 PM
$OGEN I can’t wait for the day I look at this stock and it’s over $2, I’m in long so let’s see some movement
0 · Reply
hyerize
hyerize May. 14 at 10:49 PM
$OGEN for the last 4 day's i witnessed $AIIO go from .50 to $9.20 wtf! My brain hurts 👀 But also suddenly we got a new possible pandemic surging as a hauntavirus 👀 Could definitely be another squeeze coming soon 👀
1 · Reply
NMax
NMax May. 14 at 10:35 PM
$OGEN Delighted to continue adding long-term!! 😎 The average is absolutely loving it! 🤑🤑🤑
0 · Reply
RocketQueen
RocketQueen May. 14 at 6:43 PM
$OGEN scam and fraud company with absolutely nothing to show for the past decade. Dilution, reverse split, new trash can, dilution, reverse split, new trash can, new CEO, dilution, reverse split, new trash can.....
0 · Reply
NMax
NMax May. 14 at 6:08 PM
$GME $CRSP $OGEN continuing to load before the rally! Very excited for whats to come!! 🤑🤑🤑
0 · Reply
NMax
NMax May. 14 at 4:11 AM
$OGEN Delighted to continue to add!! 🤑🤑🤑
0 · Reply
RocketQueen
RocketQueen May. 14 at 12:20 AM
$OGEN more dilution for SIGY blood laundering scam, and so get ready for another major price drop...The nasal scam is unlikely to pass clinical trials and prepare for a blood bath there as well..
0 · Reply
aperzy20
aperzy20 May. 13 at 10:26 PM
$OGEN fuck this company! Down a fuck ton of money BIGGEST mistake of my life
0 · Reply
NMax
NMax May. 13 at 2:48 PM
$GME $CRSP $OGEN It looks like the borrowing of liquidity between different assets is becoming dangerously unstable for the idiotic bears. Patience. Accumulate. Patience. 😎
0 · Reply